Although miR-155 and miR-126 have been demonstrated to promote intestinal inflammation in IBD by inhibiting the expression of NF-κB inhibitor IκBα [59, 60], they are not the miRNA targets in HPM treatment on Tianshu and Qihai of experimental CD rats, indicating that HPM has specificity in terms of gene regulation. The gene discussed is NFKBIA; the disease is inflammatory bowel disease.